|
Canada-BC-ABBOTSFORD Azienda Directories
|
Azienda News:
- Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in . . .
According to the National Comprehensive Cancer Network (NCCN) 2019 guidelines on multiple myeloma (MM) treatment, three-drug regimens using bortezomib (V) and dexamethasone (d) in combination with either lenalidomide (R), (VRd) or Cyclophosphamide (C) combination (VCd) are standard first-line treatment options in newly diagnosed multiple
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly . . .
Given the excellent activity of lenalidomide seen in the phase 3 trials of lenalidomide and dexamethasone, and the promising results seen with the combination of thalidomide with alkylating agents, we designed this study to examine the efficacy of adding cyclophosphamide to lenalidomide and dexamethasone (CRd) [10,11,14] We saw excellent
- Lenalidomide, Cyclophosphamide and weekly Dexamethasone
Lenalidomide is structurally related to thalidomide, which is known to induce neuropathy However, published data suggests that significant neurotoxicity is uncommon
- Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE . . .
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed refractory myeloma patients; a phase I II study Br J Haem 2010; 150 ;3 ;326-333
- A comparison of lenalidomide dexamethasone versus cyclophosphamide . . .
We retrospectively compared the results of three consecutive phase 2 clinical trials; RD (lenalidomide dexamethasone, n=34), CRD (cyclophosphamide lenalidomide dexamethasone, n=53) and CyBorD (cyclophosphamide bortezomib dexamethasone, n=63) (N=150)
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain . . .
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) is an effective combination for treatment of AL amyloidosis and leads to durable hematologic responses as well as organ responses with manageable toxicity
- Efficacy of lenalidomide in association with cyclophosphamide and . . .
Here, we describe a relapse of MM with bilateral retro-orbital localisation without any bone involvement with good and rapid response to therapy with lenalidomide, dexamethasone, and cyclophosphamide Keywords: multiple myeloma, extramedullary disease, ocular involvement, lenalidomide
- A comparison of lenalidomide dexamethasone versus cyclophosphamide . . .
Treatment consisted of four 28-d cycles of oral lenalidomide 25 mg on days 1–21, cyclophosphamide 300 mg m 2 on days 1, 8, 15, and dexamethasone 40 mg on days 1, 8, 15, 22 Patients receiving CyBorD were enrolled between December 2006 and October 2008
- Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in . . .
According to the National Comprehensive Cancer Network (NCCN) 2019 guidelines on multiple myeloma (MM) treatment, three-drug regimens using bortezomib (V) and dexamethasone (d) in combination with either lenalidomide (R), (VRd) or Cyclophosphamide (C) combination (VCd) are standard first-line treatment options in newly diagnosed multiple
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly . . .
The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM) Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses We designed this trial to study the combination of cyclophosphamide, …
|
|